mRNA expression signature of Gleason grade predicts lethal prostate cancer - Wikidata - awgldk - TriplyDB

mRNA expression signature of Gleason grade predicts lethal prostate cancer

mRNA expression signature of Gleason grade predicts lethal prostate cancer

http://www.wikidata.org/entity/Q35023464

about

Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production Blood-based biomarkers of aggressive prostate cancer.Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.Molecular differences in transition zone and peripheral zone prostate tumors.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer RNA biomarkers to facilitate the identification of aggressive prostate cancer Cancer/testis antigens and urological malignancies Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy.Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview MicroRNAs in prostate cancer.The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification.Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Prognostic determinants in prostate cancer.Patented prostate cancer biomarkers.Novel approaches for the identification of biomarkers of aggressive prostate cancer Biomarkers in localized prostate cancer.A four gene signature predictive of recurrent prostate cancer.HES6 promotes prostate cancer aggressiveness independently of Notch signalling.Does true Gleason pattern 3 merit its cancer descriptor?Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer.The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.Prognostic Utility of a New mRNA Expression Signature of Gleason Score.Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.Screening of Target Genes and Regulatory Function of miRNAs as Prognostic Indicators for Prostate Cancer.Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

P2860

Q26852766-DBDA76F0-CD9A-4EED-B32A-07CFBA82EB8D Q27001399-A95444A6-7637-4EAA-84F3-5660528BBE0E Q28534277-9946608E-0748-4C6B-806C-2093FB030617 Q30938412-03AD9ED4-C298-4914-B424-12618324D27B Q33565740-EAE7B59F-D7A6-49F9-8FDB-D9E6B54F9FFE Q34151167-338FB0C2-86DC-4267-8EFC-8085B6DCC53D Q34448124-6A57C432-3C51-4C8C-83B0-692C121C7658 Q34448347-A7EEE680-D86B-44D9-A03D-9048632EB08C Q34847101-90EF78A5-2495-4F22-B133-CE0B5B65F5D5 Q35790108-8FE95795-009E-4C6F-A5C8-06AA962986CE Q36035812-76EA950F-1E88-45F0-B223-6B59CE8D8CD3 Q36043833-4630AA3D-9A88-42C3-B841-366174A87DCC Q36067907-DCD2A248-C220-4F04-8274-5C605B90CC11 Q36199762-084BE3E7-7A60-4F52-A9AA-F5AA90FF6451 Q36260364-A5D19F4E-E8F4-4EE5-9FAE-06F5170905A4 Q36337004-54EB9385-59A2-4517-A358-C121C1D092BF Q36417640-3D5AB53A-B469-4BCD-870C-84AB6195A89D Q36455680-5EBD6937-20F0-4A89-BC16-A29EBF789C0B Q36979944-201B1E6D-89D2-45B4-9E2F-139AA5692992 Q37291033-D5888158-677C-4C09-8180-981384403F61 Q37481246-8040251A-A969-455A-9568-F7ADBFF1B45C Q37534159-935D0119-15DC-47D3-B143-C6DB4AF6160B Q37619763-BE9107DE-B6A6-4830-88DE-8A9C73CCA6F6 Q37966912-35C91194-D77F-499D-87A3-9D6D86361F04 Q38023110-160F95B1-55EB-4E7A-B1D4-6E8067EAB179 Q38117841-6B3B76F0-56F5-4E1D-BE2A-6B95F4A037C9 Q38697114-BE85DCF6-9746-494B-B46C-7133052BB367 Q38783018-DBB53151-E71C-4302-A006-7FB114900E20 Q38888488-35DADFB7-6B8A-4D14-8767-46FCA7E04927 Q38928930-831E12AF-2B90-434F-9164-DB419964FFB7 Q38984564-4E8DE8BE-0629-4E21-BACB-05F454793305 Q39286062-1B864A3E-695B-494A-8E26-D1D688B08194 Q39356307-05E787C2-4DA2-4B12-B2DE-19E86C557745 Q39946238-1DE42816-F3DA-48E4-81A8-8DC94EA82555 Q40058263-D5B85706-BA80-4D6D-912E-3264401374E3 Q40204742-1E8B7722-795C-4427-B0F3-B6530F4BBA69 Q40251268-9A72ED2A-C692-437C-9FD4-45B8AC7F28A2 Q40356316-EA7A0197-27B3-4837-A725-F4DD8920384B Q40971970-847308CA-A2A0-4E64-A991-2E9A5AD43BB5 Q41564129-C0BE9095-9D17-4A86-B584-585FED44F8C9

P2860

mRNA expression signature of Gleason grade predicts lethal prostate cancer

http://www.wikidata.org/entity/Q35023464

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@ast

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@en

type

label

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@ast

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@en

prefLabel

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@ast

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@en

P1433

Q35023464-40FBCDDF-C546-48D8-B0C0-C35F1DD586A6

P1476

Q35023464-DBFDEFBE-E022-4B26-AA93-89B83DEC5C9E

P2093

Q35023464-11620256-0663-4D46-9715-87078EF89FD9

Q35023464-17589742-F7A1-4B4A-898F-C69B6422E0A0

Q35023464-4C973E7A-168D-4A11-ACD5-F8CEC2DBE0BF

Q35023464-75E76745-28DD-49A7-B9DA-966FE9183201

Q35023464-828DBC56-0ADA-430C-8532-63CCD09CA8C6

Q35023464-85D004DA-6256-4443-A1F9-CA17CEAB096A

Q35023464-99D73CB8-0E02-414F-97C7-FBD7A93214AE

Q35023464-B603DFAD-4CBB-4A83-A584-8A73192102FD

Q35023464-D625D20C-7664-456E-BF05-BB5259F1214A

Q35023464-D6BE92EC-545D-4477-9514-13B12C8A720D

P2860

Q35023464-0C3A5114-1878-4654-BDFC-B16C591E7F4A

Q35023464-109A1A0F-DEE5-47D8-B763-F59EEF76AEDF

Q35023464-16E4D256-EB5A-4731-89CB-F8005D223ED4

Q35023464-28F92911-8AED-475C-A256-553B655F8EEA

Q35023464-46638CEF-A8DF-4414-8304-83AD5D26F964

Q35023464-4B9A8A0E-D4AF-4A30-B10D-586A124C9095

Q35023464-5B8E1D72-51E8-47B2-9EAB-B7A917C21731

Q35023464-5BEBE616-AF7F-4300-88B1-F19C8C4356CB

Q35023464-7AC6E837-F0FB-4679-A499-2EA809F67D52

Q35023464-8342BBB7-891C-4F48-BAA1-5C67E9A4CFE8

P304

Q35023464-04172B24-EDE9-459C-BF22-329CB0ACD98A

P31

Q35023464-508D36A5-5D63-4CF1-AB2D-BA216AD88EDD

P356

Q35023464-13123E6C-C3CD-4E15-9830-C890EA1986DB

P407

Q35023464-90FCB7FD-1089-49CE-8A77-9BA29A1F4691

P433

Q35023464-59AB2490-9EA9-4489-AF6F-BACC447703AE

P478

Q35023464-9CC89261-322E-4C81-A738-B447482FAD34

P50

Q35023464-0A9827A3-4185-4849-B624-34A61EE60796

Q35023464-0D61CFD1-C760-4711-B2D0-D1599247FB72

Q35023464-18C19832-EC20-44A3-9AFC-37F992906E2D

Q35023464-54CFBC8C-B507-4941-BFF5-0D3C93B231BF

Q35023464-6AE9E821-BEAD-4F71-9D99-3D33982FD755

Q35023464-7C0DDA7F-3868-46C1-B6D5-31DAE73B4402

Q35023464-8A3856E0-873C-46C7-B5E8-50922CB36E46

Q35023464-A9F8CF6B-41AF-4CFC-8BFC-3907D702B41A

Q35023464-BD2AFBB7-98B9-4A1C-9818-B15B1DC0B2B0

Q35023464-C75379F6-869D-4E3B-90CD-EB4C854030C4

P577

Q35023464-0E24ABBA-4792-41D4-9E69-7629F0D45E0D

P698

Q35023464-A04DD123-1B5E-4C91-BD68-7EE3CCA31B63

P932

Q35023464-9C198E97-777B-4427-AD20-52A1401D1828

P356

JCO.2010.32.6421

P1433

Journal of Clinical Oncology

P1476

mRNA expression signature of Gleason grade predicts lethal prostate cancer

@en

P2093

Howard D Sesso

http://www.w3.org/2001/XMLSchema#string

Jan-Erik Johansson

http://www.w3.org/2001/XMLSchema#string

Jennifer A Sinnott

http://www.w3.org/2001/XMLSchema#string

Kathryn L Penney

http://www.w3.org/2001/XMLSchema#string

Matthew L Freedman

http://www.w3.org/2001/XMLSchema#string

Michelangelo Fiorentino

http://www.w3.org/2001/XMLSchema#string

Neil Martin

http://www.w3.org/2001/XMLSchema#string

Ove Andrén

http://www.w3.org/2001/XMLSchema#string

Sunita Setlur

http://www.w3.org/2001/XMLSchema#string

Sven Perner

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Diagnosis of multiple cancer types by shrunken centroids of gene expression

Screening and prostate-cancer mortality in a randomized European study

Final report on the aspirin component of the ongoing Physicians' Health Study

Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort.

Integrative molecular concept modeling of prostate cancer progression.

Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy.

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

P304

2391-2396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.6421

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Stephen P. Finn

Jennifer R Stark

Philip W. Kantoff

Hans-Olov Adami

Lorelei A Mucci

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21537050

http://www.w3.org/2001/XMLSchema#string

P932

3107753

http://www.w3.org/2001/XMLSchema#string